Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab, Tremelimumab and Radioembolisation in Metastatic HCC
NCT05809869Phase 2Recruiting
- Sponsor
- The University of Hong Kong
- Start
- Feb 2023
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in hepatocellular carcinoma (HCC), sponsored by The University of Hong Kong. Primary endpoints: Best Objective Response at 3 years and Rate of Abscopal Effect at 3 years. Started Feb 2023; status: recruiting.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05809869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05809869.